VectivBio (NASDAQ:VECT) & Cognition Therapeutics (NASDAQ:CGTX) Critical Review

Cognition Therapeutics (NASDAQ:CGTX) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cognition Therapeutics and VectivBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	0	2	4	0	2.67
VectivBio	0	0	0	0	N/A

Cognition Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 1,898.50%. Given Cognition Therapeutics’ higher possible upside, equities analysts plainly believe Cognition Therapeutics is more favorable than VectivBio.

Insider and Institutional Ownership

43.3% of Cognition Therapeutics shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by insiders. Comparatively, 9.7% of VectivBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Cognition Therapeutics and VectivBio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$25.79 million	($0.92)	-0.44
VectivBio	$27.34 million	N/A	-$93.74 million	N/A	N/A

Cognition Therapeutics has higher earnings, but lower revenue than VectivBio.

Profitability

This table compares Cognition Therapeutics and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-118.11%	-84.49%
VectivBio	N/A	N/A	N/A

Summary

Cognition Therapeutics beats VectivBio on 5 of the 8 factors compared between the two stocks.

About Cognition Therapeutics

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.